CPA
TVGN icon

Capital Performance Advisors’s Tevogen Bio Holdings TVGN Stock Holding History

Capital Performance Advisors’s Portfolio TVGN Stock Details TVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9
Closed -$175 – 2787
2024
Q3 		$175 Buy
+9
New +$263 ﹤0.01% 2587

Other funds holding TVGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Capital Performance Advisors's TVGN Position: Q4 2024 in Review

Capital Performance Advisors sold out of Tevogen Bio Holdings (TVGN) in Q4 2024, closing a stake of 9 shares — an estimated $175 sold.

Capital Performance Advisors first reported a position in TVGN in Q3 2024 and held it in 1 quarter. The position peaked at $175 in Q3 2024. 44 funds tracked by Wall St. Rank hold TVGN as of Q4 2024.

  • Capital Performance Advisors reported no remaining Tevogen Bio Holdings position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 9 Tevogen Bio Holdings shares in Q4 2024, an estimated $175.
  • Capital Performance Advisors first reported a position in Tevogen Bio Holdings in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Tevogen Bio Holdings position peaked at $175 in Q3 2024.
  • 44 funds tracked by Wall St. Rank held Tevogen Bio Holdings as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.